AED evaluated
| | | |
Phenobarbital
| | |
2
nd
AED
|
-
|
-
|
-
|
-
|
-
|
-
|
3
rd
AED
|
-
|
-
|
-
|
-
|
-
|
-
|
4
th
AED
|
-
|
-
|
-
|
-
|
-
|
-
|
No of dogs
|
20
|
15
|
44
|
7
|
37
|
After exclusion: 88
|
| | | | | |
Before exclusion: 102
|
Period of treatment (months)
|
approx. 6
|
mean 15; range 7.3-32
|
mean 5.9 +/−0.4
|
Unclear
|
mean 50.4; range 8-18
|
5
|
Dose of AED(s) (mg/kg)
|
mean 4.11; range 3.9-4.9 PO BID
|
Range 5–17 PO SID
|
mean 6; range 4–13 PO SID
|
median 180; mean 283; range 60–900 PO SID
|
mean 2.5 PO BID
|
2-6 PO BID
|
Pre-treatment SF (seizures/month)
|
mean 4.4 +/− 6.3 (recorded over a period of at least 6 weeks)
|
NA
|
mean 1.71 (recorded over a period of 9 m)
|
median 12; mean 14.3; range 4–28 (period not reported)
|
mean 8 seizures in total (period not reported)
|
2.4
|
Post-treatment SF (seizures/month)
|
mean 0.4 +/− 0.9
|
NA
|
mean 0.59
|
median 1; mean 1; range 0-4
|
mean 0.9
|
1.1
|
No of dogs that were failures
|
-
|
3/15 (20%)
|
12/44 (27%)
|
1/7 (14%)
|
10/37 (27%)
|
-
|
No of dogs with >0% - <50% reduction in SF
|
2/20 (10%)
|
-
|
-
|
3/7 (43%)
|
-
|
-
|
No of dogs with ≥50% - <100% reduction in SF
|
1/20 (5%)
|
6/15 (40%)
|
28/44 (64%)
|
-
|
16/37 (43%)
|
After exclusion: 22/88 (25%)
|
| | | | | |
Before exclusion: 25/102 (24%)
|
No of dogs with 100% reduction in SF
|
17/20 (85%)
|
6/15 (40%)
|
9/44 (20%)
|
3/7 (43%)
|
11/37 (30%)
|
After exclusion: 51/88 (51%)
|
| | | | | |
Before exclusion: 56/102 (55%)
|
No of dogs with >30% reduction in SF
|
-
|
12/15 (80%)
|
37/44 (84%)
|
4/7 (57%)
|
27/37 (73%)
|
-
|
95% CI successfully treated cases
|
77% - 100%
|
60% - 100%
|
73% - 95%
|
6% - 80%
|
59% - 87%
|
After exclusion: 75% - 91%
|
| | | | | |
Before exclusion: 71% - 87%
|
Overall evidence for/against recommending the use of an AED
|
Good evidence for recommending the use of phenobarbital as a monotherapy AED.
|